Novartis' Alcon received FDA approval for its implantable AcrySof IQ ReSTOR +2.5 Diopter intraocular lens, enabling vision correction at all distances in eye care patients with or without presbyopia who undergo cataract surgery.
Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.
The U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences, whose hep C drugs vaulted it to the top, according to PMLiVE based on sales info from GlobalData.
Novartis already has some positive data for Arzerra, a chronic lymphocytic leukemia (CLL) drug it picked up in its $16 billion buyout of GlaxoSmithKline's cancer drugs. Given the competition in the category, Novartis can use whatever boost it can get as it works to extract additional sales out of the portfolio of oncology products.
A Dutch immuno-oncology player that has received venture funding from Johnson & Johnson, Novartis and Pfizer is preparing to list on Nasdaq. The company--Merus--hopes to raise upward of €100 million ($107 million) to advance its pipeline of bispecific IgG antibodies into the clinic and through early-phase trials.
Adaptimmune Therapeutics has become one of the brightest hopes in the U.K. biotech scene, scoring a $350 million collaboration pact with GlaxoSmithKline and a whopping $104 million venture round. Now Adaptimmune--a 2014 Fierce 15 company--will see if it can keep the hot streak rolling with a $150 million IPO pitch.
Novartis and Juno Therapeutics, pioneers in a promising new field of cancer treatment, have reached a settlement in their long-running patent dispute, clearing the way for each to advance rival therapies designed to weaponize the immune system.
Did Novartis and Roche campaign against study data supporting cheap Avastin eye injections as a substitute for their own purpose-made vision drug Lucentis? The BMJ says they did, aiming to "undermine and divert attention" from trials pitting Lucentis against the much cheaper treatment.
Pharma heavyweight Novartis has stepped in to help bankroll Berkeley, CA-based Caribou Biosciences, one of the upstart leaders in the race to develop the cutting-edge CRISPR-Cas9 gene editing technology.
The European Medicines Agency (EMA) is preparing to step up its conditional approval initiative to cut the time and data needed to bring new drugs to patients. Having received applications to enter 58 drugs into the program, EMA has selected a treatment based on genes, cells or tissue engineering as the first candidate to advance to the next stage.